Drugs / SW1115C3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05198752 | Mar 2022 → Dec 2023 | neoplasm | Stemirna Therapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SW1115C3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05198752 ↗ |
| Modality | Messenger RNA (mRNA) | “a neoantigen mRNA personalised cancer vaccine” NCT05198752 ↗ |
| Route | Subcutaneous | “Subcutaneous Injection” NCT05198752 ↗ |